571 related articles for article (PubMed ID: 26342731)
1. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Khanna R; Bressler B; Levesque BG; Zou G; Stitt LW; Greenberg GR; Panaccione R; Bitton A; Paré P; Vermeire S; D'Haens G; MacIntosh D; Sandborn WJ; Donner A; Vandervoort MK; Morris JC; Feagan BG;
Lancet; 2015 Nov; 386(10006):1825-34. PubMed ID: 26342731
[TBL] [Abstract][Full Text] [Related]
2. Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT.
Singh S; Stitt LW; Zou G; Khanna R; Dulai PS; Sandborn WJ; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2019 May; 49(9):1188-1194. PubMed ID: 30891808
[TBL] [Abstract][Full Text] [Related]
3. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
D'Haens G; Baert F; van Assche G; Caenepeel P; Vergauwe P; Tuynman H; De Vos M; van Deventer S; Stitt L; Donner A; Vermeire S; Van De Mierop FJ; Coche JR; van der Woude J; Ochsenkühn T; van Bodegraven AA; Van Hootegem PP; Lambrecht GL; Mana F; Rutgeerts P; Feagan BG; Hommes D; ;
Lancet; 2008 Feb; 371(9613):660-667. PubMed ID: 18295023
[TBL] [Abstract][Full Text] [Related]
4. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
5. Crohn's disease management after intestinal resection: a randomised trial.
De Cruz P; Kamm MA; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Gibson PR; Sparrow M; Leong RW; Florin TH; Gearry RB; Radford-Smith G; Macrae FA; Debinski H; Selby W; Kronborg I; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
Lancet; 2015 Apr; 385(9976):1406-17. PubMed ID: 25542620
[TBL] [Abstract][Full Text] [Related]
6. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
7. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
Ardizzone S; Bollani S; Manzionna G; Imbesi V; Colombo E; Bianchi Porro G
Dig Liver Dis; 2003 Sep; 35(9):619-27. PubMed ID: 14563183
[TBL] [Abstract][Full Text] [Related]
8. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):343-355. PubMed ID: 36736339
[TBL] [Abstract][Full Text] [Related]
9. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA;
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644
[TBL] [Abstract][Full Text] [Related]
10. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Cosnes J; Bourrier A; Laharie D; Nahon S; Bouhnik Y; Carbonnel F; Allez M; Dupas JL; Reimund JM; Savoye G; Jouet P; Moreau J; Mary JY; Colombel JF;
Gastroenterology; 2013 Oct; 145(4):758-65.e2; quiz e14-5. PubMed ID: 23644079
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
[TBL] [Abstract][Full Text] [Related]
12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
13. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
Dassopoulos T; Sultan S; Falck-Ytter YT; Inadomi JM; Hanauer SB
Gastroenterology; 2013 Dec; 145(6):1464-78.e1-5. PubMed ID: 24267475
[No Abstract] [Full Text] [Related]
14. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
16. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Noor NM; Lee JC; Bond S; Dowling F; Brezina B; Patel KV; Ahmad T; Banim PJ; Berrill JW; Cooney R; De La Revilla Negro J; de Silva S; Din S; Durai D; Gordon JN; Irving PM; Johnson M; Kent AJ; Kok KB; Moran GW; Mowat C; Patel P; Probert CS; Raine T; Saich R; Seward A; Sharpstone D; Smith MA; Subramanian S; Upponi SS; Wiles A; Williams HRT; van den Brink GR; Vermeire S; Jairath V; D'Haens GR; McKinney EF; Lyons PA; Lindsay JO; Kennedy NA; Smith KGC; Parkes M;
Lancet Gastroenterol Hepatol; 2024 May; 9(5):415-427. PubMed ID: 38402895
[TBL] [Abstract][Full Text] [Related]
17. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
Schulberg JD; Wright EK; Holt BA; Hamilton AL; Sutherland TR; Ross AL; Vogrin S; Miller AM; Connell WC; Lust M; Ding NS; Moore GT; Bell SJ; Shelton E; Christensen B; De Cruz P; Rong YJ; Kamm MA
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):318-331. PubMed ID: 34890567
[TBL] [Abstract][Full Text] [Related]
18. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
[TBL] [Abstract][Full Text] [Related]
20. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.
Mowat C; Arnott I; Cahill A; Smith M; Ahmad T; Subramanian S; Travis S; Morris J; Hamlin J; Dhar A; Nwokolo C; Edwards C; Creed T; Bloom S; Yousif M; Thomas L; Campbell S; Lewis SJ; Sebastian S; Sen S; Lal S; Hawkey C; Murray C; Cummings F; Goh J; Lindsay JO; Arebi N; Potts L; McKinley AJ; Thomson JM; Todd JA; Collie M; Dunlop MG; Mowat A; Gaya DR; Winter J; Naismith GD; Ennis H; Keerie C; Lewis S; Prescott RJ; Kennedy NA; Satsangi J;
Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):273-282. PubMed ID: 28404197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
